Symbols / APLS Stock $41.06 +0.10% Apellis Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
APLS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Cedric Francois M.D., Ph.D.
Exch · Country NMS · United States
Market Cap 5.26B
Enterprise Value 5.33B
Income 133.27M
Sales 1.11B
FCF (ttm) -63.65M
Book/sh 3.24
Cash/sh 3.17
Employees 733
Insider 10d —
IPO Nov 09, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 38.37
Forward P/E -188.12
PEG —
P/S 4.76
P/B 12.66
P/C —
EV/EBITDA 31.96
EV/Sales 4.82
Quick Ratio 3.00
Current Ratio 3.63
Debt/Eq 114.66
LT Debt/Eq —
EPS (ttm) 1.07
EPS next Y -0.22
EPS Growth —
Revenue Growth 60.90%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-30
Earnings (prior) 2026-05-07
ROA 10.93%
ROE 46.02%
ROIC —
Gross Margin 64.28%
Oper. Margin 9.87%
Profit Margin 12.06%
Shs Outstand 128.02M
Shs Float 83.22M
Insider Own 13.25%
Instit Own 93.95%
Short Float 12.55%
Short Ratio 1.15
Short Interest 10.75M
52W High 41.14
vs 52W High -0.19%
52W Low 16.10
vs 52W Low 155.03%
Beta -0.25
Impl. Vol. 0.39%
Rel Volume 1.18
Avg Volume 5.38M
Volume 6.33M
Target (mean) $40.93
Tgt Median $41.00
Tgt Low $40.00
Tgt High $41.00
# Analysts 15
Recom Hold
Prev Close $41.02
Price $41.06
Change 0.10%
About

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$40.93
Mean price target
2. Current target
$41.06
Latest analyst target
3. DCF / Fair value
$-8.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$41.06
Low
$40.00
High
$41.00
Mean
$40.93

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-10-16 init Scotiabank — → Sector Perform $35
2024-10-16 init William Blair — → Outperform —
2024-09-24 main Wells Fargo Equal-Weight → Equal-Weight $43
2024-09-23 main Baird Outperform → Outperform $92
2024-09-20 main Mizuho Neutral → Neutral $39
2024-09-20 reit Needham Buy → Buy $85
2024-09-13 main JP Morgan Overweight → Overweight $57
2024-08-13 main JP Morgan Overweight → Overweight $64
2024-08-09 main UBS Buy → Buy $83
2024-08-09 main Wedbush Neutral → Neutral $41
2024-08-09 main Goldman Sachs Buy → Buy $74
2024-08-09 main Baird Outperform → Outperform $96
2024-08-09 reit Needham Buy → Buy $85
2024-08-02 main HC Wainwright & Co. Buy → Buy $83
2024-08-02 main Goldman Sachs Buy → Buy $66
2024-08-02 reit Needham Buy → Buy $85
2024-07-31 main Jefferies Buy → Buy $80
2024-07-26 main Baird Outperform → Outperform $86
2024-07-23 main Baird Outperform → Outperform $100
2024-07-17 main Goldman Sachs Buy → Buy $77
News
RSS: Latest APLS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-29 BAUMAL CAROLINE Officer — 900 $0.00 $0
2026-04-17 SULLIVAN TIMOTHY EUGENE Chief Financial Officer — 11,096 $0.00 $0
2026-03-11 FRANCOIS CEDRIC Chief Executive Officer — 64,869 $0.00 $0
2026-02-27 DOLSTEN MIKAEL G Director — 14,312 $0.00 $0
2026-02-11 DELONG MARK JEFFREY Officer — 368 $22.15 $8,153
2026-02-03 FRANCOIS CEDRIC Chief Executive Officer — 8,840 $3.76 $33,238
2026-01-28 FRANCOIS CEDRIC Chief Executive Officer — 195,952 $0.00 $0
2026-01-28 WATSON DAVID OSBORNE General Counsel — 55,986 $0.00 $0
2026-01-28 DESCHATELETS PASCAL Officer — 25,840 $0.00 $0
2026-01-28 NICHOLSON NUR Chief Technology Officer — 45,220 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,003.78
+28.46%
781.37
+97.02%
396.59
+425.83%
75.42
Operating Revenue
1,003.78
+28.46%
781.37
+97.02%
396.59
+425.83%
75.42
Cost Of Revenue
102.24
-13.16%
117.72
+101.20%
58.51
+938.15%
5.64
Reconciled Cost Of Revenue
102.24
-13.16%
117.72
+101.20%
58.51
+938.15%
5.64
Gross Profit
901.55
+35.85%
663.64
+96.30%
338.08
+384.45%
69.79
Operating Expense
846.12
+2.11%
828.62
-3.11%
855.20
+28.72%
664.40
Research And Development
295.85
-9.68%
327.57
-7.57%
354.39
-8.48%
387.24
Selling General And Administration
550.26
+9.82%
501.05
+0.05%
500.81
+80.69%
277.16
General And Administrative Expense
—
—
500.81
+80.69%
277.16
Other Gand A
—
—
500.81
+80.69%
277.16
Total Expenses
948.36
+0.21%
946.35
+3.57%
913.71
+36.37%
670.03
Operating Income
55.43
+133.60%
-164.98
+68.10%
-517.12
+13.03%
-594.61
Total Operating Income As Reported
55.43
+133.60%
-164.98
+68.10%
-517.12
+13.03%
-594.61
EBITDA
70.00
+145.30%
-154.53
+68.79%
-495.13
+19.79%
-617.33
Normalized EBITDA
70.00
+145.87%
-152.58
+69.18%
-495.13
+15.28%
-584.43
Reconciled Depreciation
1.56
-13.30%
1.80
+0.73%
1.78
+14.95%
1.55
EBIT
68.44
+143.78%
-156.32
+68.54%
-496.92
+19.71%
-618.88
Total Unusual Items
0.00
+100.00%
-1.95
0.00
+100.00%
-32.89
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-1.95
0.00
+100.00%
-32.89
Special Income Charges
0.00
+100.00%
-1.95
0.00
+100.00%
-32.89
Other Special Charges
—
1.95
—
32.89
Net Income
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Pretax Income
24.11
+112.26%
-196.72
+62.64%
-526.50
+19.19%
-651.50
Net Non Operating Interest Income Expense
-31.18
-12.91%
-27.62
-219.36%
-8.65
+63.53%
-23.71
Interest Expense Non Operating
44.33
+9.74%
40.39
+36.54%
29.58
-9.33%
32.63
Net Interest Income
-31.18
-12.91%
-27.62
-219.36%
-8.65
+63.53%
-23.71
Interest Expense
44.33
+9.74%
40.39
+36.54%
29.58
-9.33%
32.63
Interest Income Non Operating
13.14
+2.90%
12.77
-38.98%
20.93
+134.83%
8.91
Interest Income
13.14
+2.90%
12.77
-38.98%
20.93
+134.83%
8.91
Other Income Expense
-0.13
+96.77%
-4.12
-466.57%
-0.73
+97.81%
-33.18
Other Non Operating Income Expenses
-0.13
+93.87%
-2.17
-198.49%
-0.73
-152.43%
-0.29
Gain On Sale Of Security
—
—
—
—
Tax Provision
1.72
+48.19%
1.16
-45.50%
2.13
+218.68%
0.67
Tax Rate For Calcs
0.00
-66.19%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.41
0.00
+100.00%
-6.91
Net Income Including Noncontrolling Interests
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Net Income From Continuing Operation Net Minority Interest
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Net Income From Continuing And Discontinued Operation
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Net Income Continuous Operations
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Normalized Income
22.39
+111.40%
-196.34
+62.86%
-528.63
+15.58%
-626.19
Net Income Common Stockholders
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Diluted EPS
0.18
+111.25%
-1.60
+64.04%
-4.45
+27.64%
-6.15
Basic EPS
0.18
+111.25%
-1.60
+64.04%
-4.45
+27.64%
-6.15
Basic Average Shares
126.14
+1.81%
123.91
+4.40%
118.68
+11.84%
106.11
Diluted Average Shares
129.85
+4.80%
123.91
+4.40%
118.68
+11.84%
106.11
Diluted NI Availto Com Stockholders
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Line Item Trend 2023-12-31
Total Assets
788.73
Current Assets
766.33
Cash Cash Equivalents And Short Term Investments
351.19
Cash And Cash Equivalents
351.19
Other Short Term Investments
—
Receivables
224.50
Accounts Receivable
206.44
Other Receivables
18.05
Taxes Receivable
0.00
Inventory
146.36
Raw Materials
32.72
Work In Process
82.92
Finished Goods
30.71
Prepaid Assets
38.82
Restricted Cash
1.11
Other Current Assets
4.35
Total Non Current Assets
22.40
Net PPE
21.09
Gross PPE
21.09
Other Properties
21.09
Other Non Current Assets
1.31
Total Liabilities Net Minority Interest
594.21
Current Liabilities
247.59
Payables And Accrued Expenses
165.32
Payables
37.52
Accounts Payable
37.52
Current Accrued Expenses
127.81
Current Debt And Capital Lease Obligation
6.44
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
6.44
Other Current Liabilities
75.83
Total Non Current Liabilities Net Minority Interest
346.62
Long Term Debt And Capital Lease Obligation
104.49
Long Term Debt
93.03
Long Term Capital Lease Obligation
11.45
Other Non Current Liabilities
242.13
Stockholders Equity
194.52
Common Stock Equity
194.52
Capital Stock
0.01
Common Stock
0.01
Preferred Stock
0.00
Share Issued
119.56
Ordinary Shares Number
119.56
Treasury Shares Number
0.00
Additional Paid In Capital
3,035.54
Retained Earnings
-2,837.49
Gains Losses Not Affecting Retained Earnings
-3.54
Other Equity Adjustments
-3.54
Total Equity Gross Minority Interest
194.52
Total Capitalization
287.55
Working Capital
518.74
Invested Capital
287.55
Total Debt
110.93
Net Debt
—
Capital Lease Obligations
17.89
Net Tangible Assets
194.52
Tangible Book Value
194.52
Current Provisions
—
Derivative Product Liabilities
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
45.33
+151.59%
-87.87
+85.23%
-594.74
-15.76%
-513.75
Cash Flow From Continuing Operating Activities
45.33
+151.59%
-87.87
+85.23%
-594.74
-15.76%
-513.75
Net Income From Continuing Operations
22.39
+111.31%
-197.88
+62.57%
-528.63
+18.94%
-652.17
Depreciation Amortization Depletion
1.56
-13.30%
1.80
+0.73%
1.78
+14.95%
1.55
Depreciation
1.56
-13.30%
1.80
+0.73%
1.78
+14.95%
1.55
Depreciation And Amortization
1.56
-13.30%
1.80
+0.73%
1.78
+14.95%
1.55
Other Non Cash Items
2.50
-76.22%
10.49
-60.08%
26.29
-8.27%
28.66
Stock Based Compensation
104.00
-8.87%
114.13
+7.72%
105.94
+16.31%
91.08
Operating Gains Losses
—
1.95
+1524.17%
0.12
-99.64%
32.89
Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
0.00
0.00
-100.00%
0.12
0.00
Change In Working Capital
-85.12
-363.68%
-18.36
+90.83%
-200.25
-1170.37%
-15.76
Change In Receivables
-101.28
-73.17%
-58.48
+70.57%
-198.72
-8466.95%
2.38
Changes In Account Receivables
-101.28
-73.17%
-58.48
+70.57%
-198.72
-8466.95%
2.38
Change In Inventory
-15.27
-41.95%
-10.76
+82.27%
-60.65
+12.61%
-69.40
Change In Prepaid Assets
-8.09
-125.91%
31.21
+152.27%
12.37
+207.79%
-11.48
Change In Payables And Accrued Expense
43.61
+126.65%
19.24
-45.21%
35.12
+183.75%
12.38
Change In Accrued Expense
25.39
+39.86%
18.15
-48.06%
34.95
+653.71%
-6.31
Change In Payable
18.22
+1573.37%
1.09
+540.59%
0.17
-99.09%
18.69
Change In Account Payable
18.22
+1573.37%
1.09
+540.59%
0.17
-99.09%
18.69
Change In Other Working Capital
-0.03
+87.73%
-0.28
-246.25%
-0.08
-23.08%
-0.07
Change In Other Current Assets
-4.06
-676.03%
0.70
-93.97%
11.70
-76.80%
50.43
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
-0.31
+22.33%
-0.40
+40.21%
-0.67
-101.13%
59.89
Cash Flow From Continuing Investing Activities
-0.31
+22.33%
-0.40
+40.21%
-0.67
-101.13%
59.89
Net PPE Purchase And Sale
-0.31
+22.33%
-0.40
+40.21%
-0.67
+55.77%
-1.52
Purchase Of PPE
-0.31
+22.33%
-0.40
+47.87%
-0.77
+49.28%
-1.52
Sale Of PPE
0.00
0.00
-100.00%
0.10
0.00
Capital Expenditure
-0.31
+22.33%
-0.40
+47.87%
-0.77
+49.28%
-1.52
Net Investment Purchase And Sale
—
0.00
0.00
-100.00%
61.42
Purchase Of Investment
—
0.00
0.00
+100.00%
-331.86
Sale Of Investment
—
0.00
0.00
-100.00%
393.28
Financing Cash Flow
8.88
-94.05%
149.24
-62.17%
394.50
+7.89%
365.66
Cash Flow From Continuing Financing Activities
8.88
-94.05%
149.24
-62.17%
394.50
+7.89%
365.66
Net Issuance Payments Of Debt
0.00
-100.00%
365.45
0.00
0.00
Issuance Of Debt
0.00
-100.00%
365.45
0.00
0.00
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
0.00
-100.00%
365.45
0.00
0.00
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
0.00
-100.00%
365.45
0.00
0.00
Net Common Stock Issuance
0.00
0.00
-100.00%
384.39
+1.12%
380.12
Proceeds From Stock Option Exercised
8.89
-52.76%
18.83
-75.44%
76.65
+198.01%
25.72
Net Other Financing Charges
-0.01
+100.00%
-235.04
-253.23%
-66.54
-65.60%
-40.18
Changes In Cash
53.90
-11.60%
60.97
+130.35%
-200.91
-127.81%
-88.19
Effect Of Exchange Rate Changes
1.25
+289.68%
-0.66
-588.15%
0.14
+127.66%
-0.49
Beginning Cash Position
412.61
+17.12%
352.30
-36.30%
553.07
-13.82%
641.75
End Cash Position
467.76
+13.37%
412.61
+17.12%
352.30
-36.30%
553.07
Free Cash Flow
45.01
+151.00%
-88.27
+85.18%
-595.51
-15.57%
-515.27
Interest Paid Supplemental Data
41.23
+40.40%
29.37
+793.73%
3.29
-34.32%
5.00
Income Tax Paid Supplemental Data
—
1.65
0.00
-100.00%
4.92
Common Stock Issuance
0.00
0.00
-100.00%
384.39
+1.12%
380.12
Issuance Of Capital Stock
0.00
0.00
-100.00%
384.39
+1.12%
380.12
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category